Efficacy of Interleukin-1 Targeting Treatments in Patients with Familial Mediterranean Fever

Cetin P., SARI İ., Sozeri B., Cam O., Birlik M., Akkoc N., ...More

INFLAMMATION, vol.38, no.1, pp.27-31, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 1
  • Publication Date: 2015
  • Doi Number: 10.1007/s10753-014-0004-1
  • Journal Name: INFLAMMATION
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.27-31
  • Keywords: familial Mediterranean fever, colchicine, anakinra, canakinumab, rilonacept, interleukin-1 receptor antagonist protein, amyloidosis
  • Dokuz Eylül University Affiliated: Yes

Abstract

Herein, we reported our experience in colchicine-resistant familial Mediterranean fever (FMF) patients who are treated with anti-interleukin-1 (IL-1) drugs. A retrospective review of medical records of anti-IL-1 recipients was performed. The main clinical characteristics of these patients and the evolution after anti-IL-1 were recorded. There were 20 patients (11 male [M] and 9 female [F]). Despite regular colchicine treatment, median number of attacks per month and per year was 1 (1-4) and 12 (4-50), respectively. Twelve patients were receiving anakinra, and eight patients were treated with canakinumab. The number of monthly and yearly attacks after IL-1 treatment was significantly decreased after the biologic agent (p < 0.05). One patient did not respond to the treatment, and one patient developed serious infection during anti-IL-1. We also observed a significant decrease in proteinuria in the amyloidosis complicated FMF patients. Anti-IL-1 targeting drugs seem safe and effective therapies in colchicine-resistant FMF.